Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Molecularly-Driven Doublet Therapy for All Children With Refractory or Recurrent CNS Malignant Neoplasms and Young Adults With Refractory or Recurrent SHH Medulloblastoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03434262
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:26:29.028430+00:00
Published At
2024-05-31T00:00:00+00:00
Record Updated At
2024-05-31
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Anaplastic Astrocytoma", "Anaplastic Ependymoma", "Anaplastic Ganglioglioma", "Anaplastic Meningioma", "Anaplastic Oligodendroglioma", "Pleomorphic Xanthoastrocytoma, Anaplastic", "Atypical Teratoid/Rhabdoid Tumor", "Brain Cancer", "Brain Tumor", "Central Nervous System Neoplasms", "Choroid Plexus Carcinoma", "CNS Embryonal Tumor With Rhabdoid Features", "Ganglioneuroblastoma of Central Nervous System", "CNS Tumor", "Embryonal Tumor of CNS", "Ependymoma", "Glioblastoma", "Glioma", "Glioma, Malignant", "Medulloblastoma", "Medulloblastoma; Unspecified Site", "Medulloepithelioma", "Neuroepithelial Tumor", "Neoplasms", "Neoplasms, Neuroepithelial", "Papillary Tumor of the Pineal Region (High-grade Only)", "Pediatric Brain Tumor", "Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only)", "Pineoblastoma", "Primitive Neuroectodermal Tumor", "Recurrent Medulloblastoma", "Refractory Brain Tumor", "Neuroblastoma. CNS", "Glioblastoma, IDH-mutant", "Glioblastoma, IDH-wildtype", "Medulloblastoma, Group 3", "Medulloblastoma, Group 4", "Glioma, High Grade", "Neuroepithelial Tumor, High Grade", "Medulloblastoma, SHH-activated and TP53 Mutant", "Medulloblastoma, SHH-activated and TP53 Wildtype", "Medulloblastoma, Chromosome 9q Loss", "Medulloblastoma, Non-WNT Non-SHH, NOS", "Medulloblastoma, Non-WNT/Non-SHH", "Medulloblastoma, PTCH1 Mutation", "Medulloblastoma, WNT-activated", "Ependymoma, Recurrent", "Glioma, Recurrent High Grade", "Glioma, Recurrent Malignant", "Embryonal Tumor, NOS", "Glioma, Diffuse Midline, H3K27M-mutant", "Embryonal Tumor With Multilayered Rosettes (ETMR)", "Ependymoma, NOS, WHO Grade III", "Ependymoma, NOS, WHO Grade II", "Medulloblastoma, G3/G4", "Ependymoma, RELA Fusion Positive"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-05-31"
protocolSection.identificationModule.nctId
"NCT03434262"
protocolSection.identificationModule.officialTitle
"Molecularly-Driven Doublet Therapy for All Children With Refractory or Recurrent CNS Malignant Neoplasms and Young Adults With Refractory or Recurrent SHH Medulloblastoma"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Anaplastic Astrocytoma (protocolSection.conditionsModule.conditions)
  • Anaplastic Ependymoma (protocolSection.conditionsModule.conditions)
  • Anaplastic Ganglioglioma (protocolSection.conditionsModule.conditions)
  • Anaplastic Meningioma (protocolSection.conditionsModule.conditions)
  • Anaplastic Oligodendroglioma (protocolSection.conditionsModule.conditions)
  • Pleomorphic Xanthoastrocytoma, Anaplastic (protocolSection.conditionsModule.conditions)
  • Atypical Teratoid/Rhabdoid Tumor (protocolSection.conditionsModule.conditions)
  • Brain Cancer (protocolSection.conditionsModule.conditions)
  • Brain Tumor (protocolSection.conditionsModule.conditions)
  • Central Nervous System Neoplasms (protocolSection.conditionsModule.conditions)
  • Choroid Plexus Carcinoma (protocolSection.conditionsModule.conditions)
  • CNS Embryonal Tumor With Rhabdoid Features (protocolSection.conditionsModule.conditions)
  • Ganglioneuroblastoma of Central Nervous System (protocolSection.conditionsModule.conditions)
  • CNS Tumor (protocolSection.conditionsModule.conditions)
  • Embryonal Tumor of CNS (protocolSection.conditionsModule.conditions)
  • Ependymoma (protocolSection.conditionsModule.conditions)
  • Glioblastoma (protocolSection.conditionsModule.conditions)
  • Glioma (protocolSection.conditionsModule.conditions)
  • Glioma, Malignant (protocolSection.conditionsModule.conditions)
  • Medulloblastoma (protocolSection.conditionsModule.conditions)
  • Medulloblastoma; Unspecified Site (protocolSection.conditionsModule.conditions)
  • Medulloepithelioma (protocolSection.conditionsModule.conditions)
  • Neuroepithelial Tumor (protocolSection.conditionsModule.conditions)
  • Neoplasms (protocolSection.conditionsModule.conditions)
  • Neoplasms, Neuroepithelial (protocolSection.conditionsModule.conditions)
  • Papillary Tumor of the Pineal Region (High-grade Only) (protocolSection.conditionsModule.conditions)
  • Pediatric Brain Tumor (protocolSection.conditionsModule.conditions)
  • Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only) (protocolSection.conditionsModule.conditions)
  • Pineoblastoma (protocolSection.conditionsModule.conditions)
  • Primitive Neuroectodermal Tumor (protocolSection.conditionsModule.conditions)
  • Recurrent Medulloblastoma (protocolSection.conditionsModule.conditions)
  • Refractory Brain Tumor (protocolSection.conditionsModule.conditions)
  • Neuroblastoma. CNS (protocolSection.conditionsModule.conditions)
  • Glioblastoma, IDH-mutant (protocolSection.conditionsModule.conditions)
  • Glioblastoma, IDH-wildtype (protocolSection.conditionsModule.conditions)
  • Medulloblastoma, Group 3 (protocolSection.conditionsModule.conditions)
  • Medulloblastoma, Group 4 (protocolSection.conditionsModule.conditions)
  • Glioma, High Grade (protocolSection.conditionsModule.conditions)
  • Neuroepithelial Tumor, High Grade (protocolSection.conditionsModule.conditions)
  • Medulloblastoma, SHH-activated and TP53 Mutant (protocolSection.conditionsModule.conditions)
  • Medulloblastoma, SHH-activated and TP53 Wildtype (protocolSection.conditionsModule.conditions)
  • Medulloblastoma, Chromosome 9q Loss (protocolSection.conditionsModule.conditions)
  • Medulloblastoma, Non-WNT Non-SHH, NOS (protocolSection.conditionsModule.conditions)
  • Medulloblastoma, Non-WNT/Non-SHH (protocolSection.conditionsModule.conditions)
  • Medulloblastoma, PTCH1 Mutation (protocolSection.conditionsModule.conditions)
  • Medulloblastoma, WNT-activated (protocolSection.conditionsModule.conditions)
  • Ependymoma, Recurrent (protocolSection.conditionsModule.conditions)
  • Glioma, Recurrent High Grade (protocolSection.conditionsModule.conditions)
  • Glioma, Recurrent Malignant (protocolSection.conditionsModule.conditions)
  • Embryonal Tumor, NOS (protocolSection.conditionsModule.conditions)
  • Glioma, Diffuse Midline, H3K27M-mutant (protocolSection.conditionsModule.conditions)
  • Embryonal Tumor With Multilayered Rosettes (ETMR) (protocolSection.conditionsModule.conditions)
  • Ependymoma, NOS, WHO Grade III (protocolSection.conditionsModule.conditions)
  • Ependymoma, NOS, WHO Grade II (protocolSection.conditionsModule.conditions)
  • Medulloblastoma, G3/G4 (protocolSection.conditionsModule.conditions)
  • Ependymoma, RELA Fusion Positive (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.